BRAF mutation predicts sensitivity to MEK inhibition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The RAS/RAF/MEK/ERK kinase pathway is frequently activated in human cancers.
• Gain-of-function mutations in RAS and RAF family members drive this activation.
• Targeting this pathway is a key strategy in cancer therapy.

Purpose of the Study:

• To investigate the differential sensitivity of tumors with BRAF versus RAS mutations to MEK inhibition.
• To elucidate the molecular mechanisms underlying MEK inhibitor sensitivity in BRAF-mutant cells.
• To evaluate the therapeutic potential of MEK inhibitors in genetically defined tumor subtypes.

Main Methods:

• Utilized small-molecule MEK inhibitors.
• Conducted integrated genetic and pharmacologic analyses.
• Compared MEK inhibition effects in BRAF-mutant, RAS-mutant, and wild-type cells and xenografts.
• Assessed changes in cyclin D1 protein expression and cell cycle arrest (G1).

Main Results:

• BRAF-mutant cells exhibited enhanced and selective sensitivity to MEK inhibition compared to wild-type or RAS-mutant cells.
• This sensitivity was independent of tissue lineage and correlated with cyclin D1 downregulation and G1 arrest.
• Pharmacological MEK inhibition led to complete tumor growth abrogation in BRAF-mutant xenografts.
• RAS-mutant tumors showed only partial inhibition with MEK inhibition.

Conclusions:

• BRAF-mutant tumors display an exquisite dependency on MEK pathway activity.
• MEK inhibitors represent a rational and effective therapeutic strategy for BRAF-mutant tumors.
• This study identifies a genetically defined tumor subtype amenable to targeted MEK inhibition.